Additionally, the 36-month beta value for BDTX is 2.78. There are mixed opinions on the stock, with 4 analysts rating it as a “buy,” 3 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for BDTX is 43.16M and currently, short sellers hold a 17.17% ratio of that float. The average trading volume of BDTX on March 25, 2025 was 3.12M shares.
BDTX) stock’s latest price update
Black Diamond Therapeutics Inc (NASDAQ: BDTX)’s stock price has plunge by -5.62relation to previous closing price of 1.78. Nevertheless, the company has seen a -1.75% plunge in its stock price over the last five trading sessions. globenewswire.com reported 2025-03-19 that SURESNES, France and CAMBRIDGE, Mass., March 19, 2025 (GLOBE NEWSWIRE) — Servier, an independent global pharmaceutical group governed by a non-profit foundation, and Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today announced a strategic worldwide licensing agreement for BDTX-4933, a potential best-in-class targeted therapy for solid tumors. Under this global agreement, Servier will develop and commercialize BDTX-4933, a small molecule designed by Black Diamond Therapeutics to address unmet medical needs in RAF/RAS-mutant solid tumors.
BDTX’s Market Performance
Black Diamond Therapeutics Inc (BDTX) has seen a -1.75% fall in stock performance for the week, with a -22.22% decline in the past month and a -28.21% plunge in the past quarter. The volatility ratio for the week is 21.74%, and the volatility levels for the past 30 days are at 11.36% for BDTX. The simple moving average for the past 20 days is -7.69% for BDTX’s stock, with a -54.45% simple moving average for the past 200 days.
Analysts’ Opinion of BDTX
Many brokerage firms have already submitted their reports for BDTX stocks, with Raymond James repeating the rating for BDTX by listing it as a “Outperform.” The predicted price for BDTX in the upcoming period, according to Raymond James is $20 based on the research report published on July 31, 2024 of the previous year 2024.
Stifel gave a rating of “Buy” to BDTX, setting the target price at $10 in the report published on June 30th of the previous year.
BDTX Trading at -21.55% from the 50-Day Moving Average
After a stumble in the market that brought BDTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -78.07% of loss for the given period.
Volatility was left at 11.36%, however, over the last 30 days, the volatility rate increased by 21.74%, as shares sank -22.58% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -17.24% lower at present.
During the last 5 trading sessions, BDTX fell by -1.75%, which changed the moving average for the period of 200-days by -65.15% in comparison to the 20-day moving average, which settled at $1.8200. In addition, Black Diamond Therapeutics Inc saw -21.50% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at BDTX starting from BIOTECH GROWTH N V, who sale 5,784,292 shares at the price of $2.07 back on Mar 19 ’25. After this action, BIOTECH GROWTH N V now owns 2,733,547 shares of Black Diamond Therapeutics Inc, valued at $11,997,749 using the latest closing price.
Versant Venture Capital VI, L., the 10% Owner of Black Diamond Therapeutics Inc, sale 221,600 shares at $6.32 during a trade that took place back on Aug 28 ’24, which means that Versant Venture Capital VI, L. is holding 3,726,341 shares at $1,400,556 based on the most recent closing price.
Stock Fundamentals for BDTX
The total capital return value is set at -0.77. Equity return is now at value -69.67, with -49.55 for asset returns.
Based on Black Diamond Therapeutics Inc (BDTX), the company’s capital structure generated 0.21 points at debt to capital in total, while cash flow to debt ratio is standing at -2.81.
Currently, EBITDA for the company is -78.78 million with net debt to EBITDA at 0.18. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.92.
Conclusion
In conclusion, Black Diamond Therapeutics Inc (BDTX) has seen bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
